Depo-Provera_ 150 mg Suspension for injection
PDF Leaflet Revision Date: 21 January 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Endometriosis, contraception, endometrial and renal cancer.
Dosage (summary)
50 mg weekly or 100 mg every 2 weeks for endometriosis; 150 mg every 3 months for contraception.
Special Populations
- Hepatic insufficiency
- Renal insufficiency
Pregnancy & Breastfeeding
Contraindicated in pregnancy; safe during breastfeeding.
Key Drug Interactions
- Aminoglutethimide may depress bioavailability
- Cytochrome P450 3A4 interactions possible
Contraindications
- Hypersensitivity to medroxyprogesterone acetate
- Undiagnosed vaginal bleeding
- Severe liver impairment
- Known or suspected pregnancy
Common side effects
- Abdominal pain
- Dizziness
- Weight fluctuation
- Nervousness
- Headache
Counselling Points
- May disrupt menstrual cycles
- Monitor for mood changes
- Does not protect against STIs
Serious warnings
- Loss of bone mineral density
- Thromboembolic disorders
- Meningioma risk
- Severe depression risk
Important Disclaimer
The Depo-Provera_ 150 mg Suspension for injection professional information leaflet below is the property of Pfizer Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
